Improving the reporting quality of intervention trials addressing the inter-individual variability in response to the consumption of plant bioactives:quality index and recommendations by Nikolic, Marina et al.
Vol.:(0123456789) 
European Journal of Nutrition 
https://doi.org/10.1007/s00394-019-02069-3
REVIEW
Improving the reporting quality of intervention trials addressing 
the inter‑individual variability in response to the consumption of plant 
bioactives: quality index and recommendations
Marina Nikolic1  · Aleksandra Konic Ristic1,2  · Antonio González‑Sarrías3  · Geoffrey Istas4  · 
Mireia Urpi‑Sarda5,6  · Margherita Dall’Asta7  · Laurent‑Emmanuel Monfoulet8  · Lieselotte Cloetens9 · 
Banu Bayram10  · Maria Rosaria Tumolo11 · Mihail Chervenkov12,13 · Egeria Scoditti14  · Marika Massaro14  · 
Noemi Tejera15  · Desislava Abadjieva16  · Karen Chambers17  · Irena Krga1  · Francisco A. Tomás‑Barberán3  · 
Christine Morand8  · Rodrigo Feliciano18 · Rocío García‑Villalba3  · Mar Garcia‑Aloy5,6  · Pedro Mena7 
Received: 2 May 2019 / Accepted: 23 July 2019 
© The Author(s) 2019
Abstract
Purpose The quality of the study design and data reporting in human trials dealing with the inter-individual variability 
in response to the consumption of plant bioactives is, in general, low. There is a lack of recommendations supporting the 
scientific community on this topic. This study aimed at developing a quality index to assist the assessment of the reporting 
quality of intervention trials addressing the inter-individual variability in response to plant bioactive consumption. Recom-
mendations for better designing and reporting studies were discussed.
Methods The selection of the parameters used for the development of the quality index was carried out in agreement with 
the scientific community through a survey. Parameters were defined, grouped into categories, and scored for different quality 
levels. The applicability of the scoring system was tested in terms of consistency and effort, and its validity was assessed by 
comparison with a simultaneous evaluation by experts’ criteria.
Results The “POSITIVe quality index” included 11 reporting criteria grouped into four categories (Statistics, Reporting, 
Data presentation, and Individual data availability). It was supported by detailed definitions and guidance for their scoring. 
The quality index score was tested, and the index demonstrated to be valid, reliable, and responsive.
Conclusions The evaluation of the reporting quality of studies addressing inter-individual variability in response to plant 
bioactives highlighted the aspects requiring major improvements. Specific tools and recommendations favoring a complete 
and transparent reporting on inter-individual variability have been provided to support the scientific community on this field.
Keywords Clinical trials · Reporting quality · Inter-individual variation · Quality index · Plant bioactive · 
Recommendations · Guidelines
Introduction
A large body of evidence supports the notion that bioactive 
compounds present in plant foods [e.g., (poly)phenols, carot-
enoids, glucosinolates, etc.] have numerous beneficial effects 
on human health, underlying the association between the 
habitual consumption of plant-based diets and the reduced 
risk of age-related chronic diseases [1, 2]. However, data 
from clinical trials aiming to establish the cause–effect rela-
tionship are often inconclusive and even contradictory [3, 
4]. It has been suggested that this may be, at least partly, 
the result of the differences in the bioavailability of plant 
bioactives among individuals, as well as the variation in 
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their effects on specific functional biomarkers, either physi-
ological or biomarkers of risk [5]. A clear understanding 
of all the factors responsible for the inter-individual vari-
ability (IIV) in response to plant bioactives is the vital part 
of knowledge that is still lacking, yet it is considered crucial 
for the ultimate positioning of plant bioactives on the road-
map to optimal health. To gain this seminal knowledge, the 
complex interactions of plant bioactives with the factors that 
drive the genotype and phenotype of individuals should be 
assessed [5–7].
A recent series of systematic reviews and meta-analyses 
of human studies addressing the IIV in response to differ-
ent plant bioactives concluded that the number of trials 
reporting between-subject variations is, in general, very low 
[8–10]. At the same time, since most studies are not initially 
designed to address IIV, they are often underpowered within 
groups and unbalanced between them, with multiple sources 
of bias including selective reporting, insufficient descrip-
tion of subjects’ characteristics and inaccurate reporting on 
statistics, as well as providing inadequate conclusions on 
the observed effects. Consequently, although in most of the 
cases the quality of protocol design and reporting of the ini-
tial study respond sufficiently to general recommendations 
and requirements [11–13] studies were often considered 
as non-adequate in terms of post hoc subgroup statistics, 
regressions, or other similar approaches in the analysis. It 
is thus evident that the design and reporting of human tri-
als addressing the between-subject variation are crucial and 
should be improved. Moreover, a better way of designing and 
reporting human intervention trials on the effect of plant bio-
actives while considering individual differences would help 
to further summarize and analyze aggregated data through 
systematic reviews and meta-analyses. An inadequate report-
ing quality of studies often makes them non-eligible to be 
included in meta-analyses or it may introduce a significant 
bias in the analysis, compromising the accuracy and reli-
ability of the conclusion [10, 14]. Nevertheless, despite the 
multiple benefits related to appropriate design and reporting 
of studies dealing with IIV in response to plant bioactive 
consumption, there is a lack of suitable recommendations 
and/or guidelines supporting the scientific community and 
favoring improvements in the way data are assessed and 
disseminated. Unfortunately, the quality assessment tools 
that are available to date [11, 15–17] do not fit sufficiently 
the scientific questions and purposes of this specific type of 
reporting of intervention trials on food products or supple-
ments rich in plant bioactives.
This study aimed at proposing a specific quality index 
(QI) as a tool to be used in the assessment of the report-
ing quality of human intervention trials addressing the IIV 
in response to plant bioactive consumption (so-called the 
“POSITIVe quality index”). The IIV QI was tested for its 
reliability, validity and responsiveness. The steps carried out 
to develop this QI have also been thoroughly reported as a 
roadmap and recommendations for its application to better 
design and report human intervention trials in the field have 
been provided.
Methods
Rationalizing the need to develop an additional tool 
to assess reporting quality and expert agreement
This study was performed as part of the COST Action 
FA1403 POSITIVe (https ://www6.inra.fr/cost-posit ive), a 
collaborative and multidisciplinary pan-European network 
of more than 300 researchers. One of the main objectives of 
the Action was to identify the main factors responsible for 
the observed IIV in response to plant food bioactives intake, 
based on available scientific evidence and generated new 
knowledge. While dealing with this objective in the early 
phases of the Action, it was noted that the reporting quality 
of human studies in the field was often limited and inad-
equate. This issue was further discussed by ten experts of the 
Action Think Tank Group (addressed in the following text as 
“score developers”). One of the main reasons hypothesized 
was the lack of generally accepted and routinely applied rec-
ommendations to report between-subject variation, either as 
primary or post hoc analysis. The strategy to solve this gap 
was defined and it consisted of several initial steps: (1) to 
review the existing literature and identify previous relevant 
guidance and assessment tools; (2) to seek relevant evidence 
on the quality of reporting in published research articles; (3) 
to identify key information related to the potential sources 
of bias in such studies; and (4) to use the POSITIVe Action 
network for expert opinions and resources.
The literature search was performed through the Equa-
tor Network Library resources (http://www.equat or-netwo 
rk.org/libra ry/), Medline, Embase and Cochrane data-
bases, and through a Pubmed search using specified 
search terms (e.g., “quality assessment”, “tools”, “report-
ing”, “guideline(s)”, “inter-individual”, “quality index”, 
“recommendation”).
The retrieved and critically selected literature included: 
(1) tools often used for assessing reporting quality of indi-
vidual studies [18] or tools for assessing reporting bias dur-
ing systematic reviews and meta-analyses [19]; (2) a scarce 
number of available resources that specifically address 
IIV in clinical trials [20–23]; (3) papers retrieved during 
the ongoing systematic searches and meta-analyses on IIV 
in response to plant bioactives; (4) two position papers of 
the Action [5, 6]; (5) several papers on “controversies” on 
clinical trial methodology and reporting [24–26]; and (6) 
available strategies on creating and developing tools and 
guidelines [27–29].
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Based on the information from the extracted literature, 
the “score developers” made a list with up to 23 criteria 
addressing all relevant parameters that may be considered 
as specific for data reporting in studies assessing IIV in 
response to plant bioactives intake (Fig. 1).
In the next step, the “score developers” designed a ques-
tionnaire entitled “How to Report Inter-Individual Variabil-
ity in Publications” that was sent to 311 members of the 
POSITIVe network. It included questions addressing expert 
opinion on (i) the need for a specific assessment tool to be 
developed; (ii) the familiarity with the Jadad score used to 
assess the quality of reports of randomized trials; (iii) the 
need for extension for this specific purpose; (iv) the inter-
est of reviewers and journal editors in the network to adopt 
and implement a quality index score (QIS) in the reviewing 
process; and, as a crucial part, (v) members were asked to 
select a number of criteria they consider relevant enough to 
be included in the score, from the list of 23 criteria made by 
the “score developers”.
Selection of categories and parameters to be 
addressed in the assessment and development 
of the IIV quality index scoring system
After collection and evaluation of the questionnaires, 
“score developers” defined the categories and selected 
the parameters within each category to be included in the 
score. Parameters selected by 50% or more experts were 
directly taken into consideration to be included in the IIV 
QI. Parameters that were considered important by 40–50% 
of experts were additionally discussed and evaluated by 
score developers, while parameters selected by less than 
40% of participants were excluded from the score. As a 
result, a list of 11 parameters grouped in 4 categories was 
defined for the design of the QI and the development of 
recommendations/guidelines for data reporting on IIV 
(Table 1).
The next step was the creation of the first version of 
a dictionary, with detailed definitions of the conditions 
related to data reporting for each parameter and with 
assigned marks, as a base for the calculation of the QIS. 
Marks were assigned to each parameter and its related con-
ditions while reporting as follows: if a particular param-
eter is not considered in the study at all, its score is 0; if 
it is reported but not informative enough to completely 
describe IIV, its score is 0.5; and, if it is considered and 
completely illustrate IIV, its score is 1. The exception to 
this scale was the last category, related to the individual 
data availability. Considering the importance of this 
parameter for the accurate assessment of IIV, develop-
ers modified the scale to 0–1–2, to increase the weight of 
this parameter in the score. The dictionary of the QI and 
parameter marks are presented and fully described in the 
results section.
Fig. 1  Percentage of experts who considered the listed parameters important to be reported when assessing inter-individual variability in 
response to consumption of plant food bioactives
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Table 1  Dictionary of conditions related to data reporting on IIV and associated scores for the evaluation of quality of data reporting in interven-
tion studies dealing with plant bioactives
Category Parameters Condition Score
Statistics Sample size-power 
calculation
Authors reported on: (1) power calculation focused on assessing inter-individual variation 
based on primary OR the most limiting outcome AND (2) on all the data used in power 
calculation (% of statistical power, significance level, expected dropout rate, expected dif-
ference between groups of the mean or % with the event) AND (3) the resulting sample size 
per each group
1
Authors did not describe sample size taking into account all the three previous conditions 0
Data distribution Authors specified the test used for normality (OR indicate something related to data normal-
ity, for instance, log transformation)
1
Authors did not report any information related to the normality or distribution of the data in 
general
0
p value Authors reported p value that support IIV (e.g., p value related to the examination of differ-
ences between two or more factors affecting IIV such as sex, age, genotypes, etc.)
1
Authors did not report any p values related to the IIV 0
Effect size Authors reported the magnitude of the IIV for the selected outcome(s) by standardized mean 
differences as an index of effect size (Cohen’s d, % of coefficient of variation, etc.) or any 
parameters related to the effect size suitable for the conducted statistical tests
1
Authors did not indicate any parameters related to the effect size i.e., magnitude of the IIV for 
the selected outcome(s) (any of standardized mean differences was not reported)
0
Reporting General characteristics 
of the subgroups 
where IIV was evalu-
ated
Authors reported on one or more general characteristics (for instance, ethnicity, BMI, age, 
gender, smoking status, etc.) for each of the subgroups where IIV was evaluated
1
Authors did not report any of general characteristics for the study sample (for instance, eth-
nicity, BMI, age, gender, smoking status, etc.) on each subgroup where IIV was evaluated
0
Data reporting for end-
points by subgroups
Both pre- and post-intervention data (or post-intervention data as % change with respect to a 
provided baseline value) were reported for different subgroups where IIV was evaluated
1
Post-intervention data (or % change without a provided baseline value) are provided by each 
subgroup where IIV was evaluated
0.5
Neither pre- nor post-intervention data were reported for different subgroups where IIV was 
evaluated
0
Measures of central 
tendencies and dis-
persion parameters
Authors reported on one or more measures of central tendencies (mean, median, etc.) AND 
one or more dispersion parameters (standard deviations, standard error, interquartile range, 
95% confidence interval, etc.) for EACH subgroup where IIV is evaluated
1
Authors did not report any measures of central tendencies or dispersion measures for 
subgroups where IIV was evaluated, regardless of reporting these parameters for the total 
sample
0
Outliers Authors indicated outliers AND described them (explained the reason for treating them as 
outliers)
1
Authors indicated that outliers existed and that were excluded from the analysis but without 
describing them
0.5
Authors did not indicate any information related to outliers 0
Data presenta-
tion
Tables Tables contain additional measures of variability (min–max, interquartile range, outliers 
values, etc.) or individual measures (responders/non-responders, etc.)
1
Tables did not contain any extra measures of variability (min–max, interquartile range, outli-
ers values, etc.) nor individual measures (responders/non-responders, etc.)
0
Graphs Authors presented data for the primary outcome by scatterplots, boxplots or heat maps 1
Authors presented data by histograms for a primary outcome OR as scatterplots and boxplots 
for secondary outcomes
0.5
Data are graphically presented as bar chart, curves, etc. (for any of the study point-before or 
after the intervention) but not as scatterplots, boxplots, heat maps or histograms
0
Individual data 
availability
Presentation of full 
data and population 
characteristics
Authors provided individual data for each end-point, together with the characteristics of the 
samples on the individual level, in the paper or in the supplemental material
2
Authors provided individual data at each end-point (even presented in the figures) but without 
any additional characteristics of the sample on the individual level
1
Authors did not provide individual data 0
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Testing the IIV quality index score validity, 
reliability, and responsiveness
In the next phase, the QI was tested and validated by evaluat-
ing and scoring existing studies, on the basis of their com-
prehensiveness of data reporting on IIV. The evaluation and 
scoring were performed by nineteen experts (“evaluators”), 
all members of the Think Tank Group of the Cost Action 
POSITIVe. Evaluators had previous experience in clini-
cal trials on plant bioactives, as shown by their publication 
records, and they were all involved in the ongoing system-
atic reviews and meta-analyses performed as part of the 
objectives of the Action [5, 8–10]. The evaluators screened 
the dossiers of peer-reviewed articles retrieved within the 
systematic searches they were involved in and identified 30 
articles that specifically reported IIV in response to plant 
bioactives consumption. The total number of 30 studies was 
considered sufficient for the purpose of testing the IIV QI.
In the first step, the comprehensiveness of the parameters 
and the dictionary was tested in a pilot trial by evaluating 
five studies. These studies were selected from the compre-
hensive list of 30 studies, using computer-assisted random 
selection from 2 subgroups, resulting in 2 random stud-
ies on bioavailability and 3 on the effects of plant bioac-
tives. Each study was evaluated independently by two or 
three different evaluators, and the final scoring was done 
based on their consensus. After the pilot testing phase, all 
evaluators provided their critical opinion to the developers 
and helped in revising the dictionary to be clear and user 
friendly. Revisions were related to the definitions of condi-
tions and regrouping parameters between categories. Once 
the final version of the dictionary for the QI was created, 30 
studies, (including 5 using in the test phase) were evaluated 
and scored in the same way as in the testing phase [30–59].
After the evaluation, data reporting quality of each study 
was assessed by the total score and four sub-scores related 
to the four categories considered: Statistics, Reporting, Data 
presentation and Individual data availability (Table 1). In 
addition to the evaluation carried out by employing the IIV 
QIS, evaluators assessed the overall quality of data reporting 
on IIV for each study using a qualitative scale and character-
izing them as weak, mild, or good based on their personal 
opinions as experts. QI was then validated by comparing 
these two methods of evaluation.
Statistics
Accuracy of QI was examined by analyzing relations 
between the quality of the studies as assessed by experts 
using quantitative scale (weak, mild, and good) and the 
QIS. The ordinal variable was created for the quality level 
assessed by experts (weak = 1, mild = 2, good = 3). The over-
all quality score was calculated for each study as the sum 
of all marks given to each study divided by 11 (number of 
selected parameters). Completeness of reporting within each 
defined category was calculated for each study as the sum 
of all marks assigned to the parameters from the category 
divided by the number of parameters for that particular cat-
egory. In this way, completeness of reporting was standard-
ized for all categories. Spearman’s correlation coefficient 
was calculated for the relation between overall IIV QIS and 
the quality level assessed by experts. Cohen’s kappa coef-
ficient was calculated to test the agreement between tertiles 
of the overall IIV QIS and quality levels assessed by the 
experts. Impact of completeness of each defined category 
within the QI on the quality levels assessed by experts was 
also assessed by the Spearman correlation coefficient. A 
value of p < 0.05 was taken to indicate a significant result. 
All analyses were performed using SPSS statistical software 
(IBM SPSS statistics 20, SPSS Inc., Chicago, IL USA).
Results
Questionnaire results
The questionnaire ‘How to Report Inter-Individual Variabil-
ity in Publications’ was answered by 66 experts involved in 
the POSITIVe network, resulting in a response rate of 21%. 
The majority of responders (96%) considered the develop-
ment of the QI important for the assessment of the qual-
ity of data reporting on IIV in publications dealing with 
plant bioactive consumption. In general, experts had dif-
ferent approaches during the selection of parameters from 
the list. The selection of fewer than ten parameters (more 
critical approach) was observed in 44% (n = 29) of those who 
answered the questionnaire. This subgroup of experts was 
focused on statistical parameters (sample size, normality, p 
value related to IIV), parameters related to the measures of 
central tendencies and dispersion, and parameters related 
to the population characteristics and stratification by dif-
ferent factors that could affect IIV. The rest of the experts 
were prone to choose more than 10 parameters, 24% of them 
selected between 11 and 15 parameters, while 32% of them 
considered more than 15 parameters as important. Answers 
provided by all responders were taken into consideration in 
further developing the QI. Percentage of experts, who con-
sidered the listed parameters important to be reported when 
assessing IIV in response to plant bioactives, is presented in 
Fig. 1. Sample size calculation, dispersion parameters, and 
population characteristics were selected by more than 70% 
of experts, as the most important parameters related to IIV. 
Data distribution, p value, mean, outliers, data before and 
after intervention by subgroups, and stratification by dif-
ferent factors (age, gender, body mass index, lifestyle, and 
health status) were considered important by more than 50% 
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of experts. However, stratification by ethnicity, hormonal 
status, polymorphism, and gut microbiota composition were 
selected by 40–50% of experts, as well as median, full data 
presented on individual level provided in the supplementary 
material, and data depicted in scatter or box plots. Graphi-
cal presentation of data distribution, individual presentation 
of non-normally distributed data, and individual data for 
study end-point were assessed as important by less than 35% 
of experts. Additional parameters under the option “other” 
were suggested by 12 experts. Only one of them (coefficient 
of variation) was related to data reporting from the statistical 
point of view, while all other parameters were more gen-
eral and not directly related to the data reporting but factors 
important for IIV, like dietary habits, physical activity, etc. 
The experts were asked about the Jadad scale for reporting 
randomized trials, and 36.4% of them stated that they were 
familiar with this scale developed in 1996 by Jadad et al. 
[15] while 59% of responders said that it would be important 
to supplement the Jadad scale with the QI related to IIV.
Among the experts who answered the questionnaire, there 
were 16 (24%) members of editorial boards in peer-reviewed 
scientific journals, with the SJR ranking for these journals 
being between 0.22 and 1.53 in 2018, including 7 with the 
SJR above 1. The majority of experts (80%) claimed that 
journal editors might be interested in the QI to be used dur-
ing the evaluation process of manuscripts dealing with IIV 
in response to plant bioactives.
Development of the quality index 
and the dictionary as associated explanatory 
document
The final version of the dictionary with defined conditions 
for each parameter and assigned scores is presented in 
Table 1. Sample size/power calculation, distribution of the 
data (normality), and p value related to the IIV were grouped 
in one category (Statistics). Additionally, after testing the 
first version of the dictionary for the QIS, evaluators stressed 
the importance of reporting on the effect size of the applied 
statistical tests, as an important parameter for the complete 
understanding of the p value significance [60]. Finally, the 
sum of scores based on the first category (Statistics) reflects 
on the quality of data reporting concerning four parameters: 
sample size/power calculation, data distribution, p value, and 
effect size. All parameters in this category could be assessed 
by a dichotomous score of 0 or 1.
Another set of six parameters listed in the questionnaire 
were regrouped into four and integrated into the second cat-
egory (Reporting) (Table 1). Reporting on general character-
istics of the subgroups where IIV is generally evaluated (age, 
gender, body mass index, smoking, etc.) was the parameter 
most often selected by experts (87.9%). Since they had 
diverse opinions about stratification according to different 
characteristics, it was decided to keep this parameter open 
for any characteristic collected for the possible study sub-
groups. Reporting on data for study end-points by subgroup 
(before and after the intervention) was also included within 
the Reporting category. Furthermore, measures of central 
tendencies and dispersion parameters reported for each 
subgroup were merged and included in this category as a 
single parameter. Reporting on outliers was integrated into 
the Reporting category as the fourth parameter. Data report-
ing on end-points by subgroups and on outliers could be 
scored by values 0, 0.5, or 1, depending on the compre-
hensiveness of the reporting (Table 1). On the other hand, 
reporting on general characteristics and measures of central 
tendencies and dispersion parameters could be scored by 0 
or 1. In conclusion, overall score related to the Reporting 
category reflects the quality of reporting on four parameters: 
general characteristics of the subgroups, data reporting for 
end-points by subgroups, measures of central tendencies and 
dispersion parameters, and outliers.
The third category considered important by developers, 
taking into account both tables and graphs (Table 1), was 
Data presentation. Though the complexity of tables was 
not listed as a parameter in the questionnaire, after testing, 
evaluators suggested to include this parameter. Its purpose 
is to assess reporting on additional values that could reflect 
IIV (min, max, interquartile range, number of responders/
producers, etc.), apart from common measures of central 
tendencies and dispersion parameters. Presenting data as 
scatter plots or box plots instead of bar charts was consid-
ered important by 49% of experts. Developers decided to 
extend this parameter to assess the global quality of graphi-
cal data presentation, making a distinction between present-
ing data on primary and secondary outcomes. It means that, 
in the final version of the dictionary, the scatter plots, box 
plots, or heat maps that depict data related to the primary 
outcome are considered as the most useful (score = 1); his-
tograms depicting primary outcome data or scatter plots/box 
plots/heat maps depicting secondary outcomes are consid-
ered as not so informative but still useful ways of illustrat-
ing IIV (score = 0.5); and bar charts, curves, etc. for any 
outcome are considered as not helpful in the assessment of 
IIV (score = 0).
The fourth category was related to the availability of 
individual data, i.e., transparency of analyzed data set and 
the possibility of further analysis. Developers distinguished 
three different levels within this category. Individual data 
available for each end-point reported together with the char-
acteristics of the study participants on an individual level 
are the most appreciated option (score = 2). Individual data 
reported for each end-point but without any additional char-
acteristics of study participants are still considered useful 
but less than the previous option (score = 1), while studies 
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that did not show any individual data are not scored for this 
category (i.e., score = 0).
Validation of the quality index‑evaluation 
of collected studies
QIS and categories sub-scores were calculated for 30 stud-
ies (Supplementary Table 1). Quality of data reporting on 
IIV for these studies was additionally evaluated by experts 
using qualitative scale, and 2 studies were assessed as weak, 
12 studies as mild, and 16 studies as good. A weak agree-
ment was found between terciles of overall QIS and the three 
levels of quality (weak, mild, and good) assessed by experts 
(Cohen’s k = 0.216, p = 0.054). The significant agreement 
between both methods was confirmed by Spearman’s rank 
correlation coefficient (r = 0.697, p < 0.001).
Numbers and percentages of studies that reported any 
data on the selected parameters (scored either 1 or 0.5 
according to the dictionary) are presented in Table 2. Sig-
nificant correlations were found between the completeness 
of particular score categories (Statistics and Reporting) and 
quality levels assessed by experts (Spearman’s r = 0.519, 
p = 0.003; r = 0.509, p = 0.004, respectively). On the con-
trary, Data presentation category was inversely correlated 
with the expert’s opinions (r = − 0.365, p = 0.047). Indi-
vidual data availability, as an independent parameter, were 
not analyzed in this way since only four studies provided 
data, but without additional characteristics of the groups 
where IIV was evaluated. Weak, mild, and good studies that 
reported on selected parameters are presented in Fig. 2. Sta-
tistics category was found as the most important for high-
quality data reporting on IIV. All studies assessed as good 
by experts reported on, at least one, parameter from the Sta-
tistics category, while 75% of them reported on two or more 
parameters from this category.
Moreover, 91% of those that reported on effect size were 
assessed as good by expert’s independent opinion. Only one 
study reported on sample size as expected (i.e., as described 
in the dictionary). Studies that reported on data distribu-
tion and p value related to IIV were assessed as good in 
67% and 61% of cases, respectively (Fig. 2). Regarding the 
Reporting category, most of the studies assessed as good by 
experts took into consideration parameters related to this 
category (Fig. 2). Results showed that 63% out of 21 stud-
ies that reported on data for end-points by subgroups were 
categorized as good by evaluators, and there were no studies 
characterized as weak. These results were similar for stud-
ies reporting on measures of central tendencies and disper-
sion parameters by subgroups (68% of them characterized 
as good). Twelve out of 20 studies (60%) that reported on 
general characteristics of the sample, where IIV was evalu-
ated, were characterized as good. Of note, studies report-
ing outliers were classified as mild according to experts’ 
opinion. Last, as suggested by the inverse correlation afore-
mentioned, graphs and tables as defined in the dictionary 
(Data presentation category) were not key parameters for 
a comprehensive explanation of IIV. Eight out of 14 stud-
ies (57%) that presented graphs as defined in the dictionary 
were assessed as weak or mild. In the case of the tables, only 
two studies reported on additional measures of variability 
(min–max, interquartile range, etc.) or individual measures 
(responders/non-responders, producers/non-producers, etc.), 
and they were assessed as mild.
Discussion
The main aim of this work was to develop a tool to support 
the assessment of the reporting quality of individual studies 
addressing either predefined or post hoc IIV in response to 
the consumption of plant bioactives. The developed tool, 
the “POSITIVe quality index” comprised 11 individual 
parameters classified into 4 categories and weighed/scored 
by criteria described in the accompanying explanatory mate-
rial—the dictionary—(available at Supplementary material 
2). The whole development process was performed as part 
of the activities of the COST Action POSITIVe and by the 
stepwise processes proposed by the Equator network col-
laborators for developers of health research reporting guide-
lines [27]. Other available and relevant recommendations on 
designing tools and general guidelines in the area of medical 
research, reporting on research data but also the dissemina-
tion of outcomes and medical practice [28, 29], were also 
taken into account.
POSITIVe quality index parameters 
and recommendations
All the parameters included in the POSITIVe QI demon-
strated to be useful for an adequate reporting of the IIV 
associated with the consumption of plant bioactives, both 
in bioavailability and bioactivity studies. Instead of empha-
sizing the parameters thoroughly described in the diction-
ary (Table 1), some aspects are worth discussing. During 
the selection of individual parameters to be included in the 
POSITIVe QI, individual data availability was considered 
a useful parameter to be reported to understand IIV fully. 
Moreover, as defined in the dictionary, individual data for 
each end-point together with the individual subject char-
acteristics (age, gender, ethnicity, etc.) are of the greatest 
value, not only for understanding the IIV at a trial level but 
also for further data aggregation and meta-analyses [61]. 
Although the practice of data sharing significantly increases 
in the clinical research community, we found only 4 out of 
30 studies on plant bioactives that provided individual data 
(but without additional characteristics of the subjects at 
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the individual level) [30, 31, 52, 55]. Therefore, in order 
to contribute to better handling and understanding the IIV 
in human intervention trials, it is highly recommended for 
authors to prepare their data for sharing either in publica-
tions or in one of the existing research data repositories such 
as ClinicalTrials.gov or repositories of the Open Research 
Data Pilot of the European Commission, based on an ade-
quate Data Management Plan [62]. Ohmann et al. summa-
rized all the principles and recommendations for Individual 
Participant Data (IPD) sharing that should be followed in 
data sharing processes [63]. In case that authors decide not 
to share IPD, comprehensive data reporting on other cat-
egories of the QI are recommended all along the scientific 
process.
Regarding the study design procedure, proper Statistics 
should be taken into account, starting from the sample 
size calculation. An adequate calculation of the sample 
size is an essential element of high-quality data report-
ing on IIV. After the evaluation of the studies regarding 
power calculation and sample size, we found that condi-
tions given in the dictionary are too demanding for this 
research area. There are still not enough studies, dealing 
with the effects of plant bioactives that reported on IIV 
between different groups, that authors could use to learn 
the population standard deviation of particular groups 
and related interventions. That is likely the reason why 
we found only one study [31] that took into consideration 
IIV for the sample size calculation. However, it is highly 
advisable to look for all studies that reported on similar 
results and, if they exist, to take into account reported IIV 
to calculate sample size.
Reporting on the distribution of data when dealing with 
IIV is as important as for all other data reporting cases, but 
we want to emphasize the importance of checking data dis-
tribution and other assumptions that should be met to get 
accurate statistical results. Misunderstandings of assump-
tions that need to be satisfied before employing parametric 
tests happen often. For example, the assumption for depend-
ent t test that the sampling distribution of the differences 
between scores of two measures should be normal is usually 
misinterpreted by a normal distribution of scores themselves. 
The assumption of normal distribution within the groups, 
which is required when employing one-way ANOVA, is mis-
interpreted as the normal distribution of the total sample, 
etc. Assumptions for the extended list of parametric tests are 
explained in detail by Field et al. [64]. Visual methods for 
checking normality like histograms, box plots, stem-and-leaf 
plots, etc. could be helpful for large data sets, since statistical 
Fig. 2  Number and percentage of good, mild, and weak studies with respect to the reported parameters within defined categories
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tests (e.g., Kolmogorov–Smirnov test, Shapiro–Wilk test, 
etc.) could be significant, i.e., rejecting the hypothesis of 
normal distribution even if deviations from normality are 
small. On the other hand, for small samples (< 30), statis-
tical tests are fully necessary [65]. Shapiro–Wilk test is 
recommended as the best choice for testing the normality 
of data [66]. Then, based on data distribution, the proper 
statistics should be used and justified, since, for example, 
the presence of responders and non-responders (or produc-
ers and non-producers) may condition the data distribution. 
Although it could be assumed that researchers are checking 
the assumptions needed to use a particular test, reporting on 
that would indicate undeniably that those assumptions have 
been assessed.
Reporting on p value, without reporting on central ten-
dencies and dispersion measures or the change by sub-
groups, is not as informative as p value reported together 
with these parameters. For example, reporting on p value 
related to different effects between men and women, as an 
explanation of a scatter plot, without reporting on mean and 
SD for each subgroup, is not as informative as it would be 
if authors provide these data numerically, especially if dif-
ferences are small. This type of reporting cannot be used in 
further meta-analysis related to the IIV, unnecessarily limit-
ing the understanding of IIV by not reporting on data that 
definitely exist. Moreover, these data could not be helpful 
for sample size calculation in future studies. Thus, reporting 
on p value should always be followed by reporting on central 
tendencies and dispersion measures for compared groups.
An additional parameter important for understanding the 
statistical significance of the effects of the intervention (p 
value) is the effect size. Even though the p value provides 
the information that effect of the intervention exists or not, 
it does not indicate the size of the effect (magnitude of the 
difference between groups/treatments) [67]. As shown in the 
results section, 91% of studies that reported on effect size 
were assessed by experts as good, regarding the quality of 
data reporting on IIV. Thus, it is highly recommended to 
report on the effect size together with the p value. In the 
studies evaluated, an informative way to report the effect size 
was using percent coefficient of variations, but further guid-
ance on how to calculate and interpret an effect size for dif-
ferent types of analysis is summarized by Durlak et al. [68].
Although 61% of studies that presented data graphically 
as defined in the dictionary were assessed by experts as weak 
or mild, we still recommend proper graphical representation 
of data. As the effect size provides additional explanation 
to the p value, appropriate graphs could disclose statistics 
reported in tables. This is especially important for small 
sample sizes, as it is usually the case of nutritional inter-
vention studies. Among the different graphs that can be used 
to represent IIV, scatterplots of raw data could be the most 
useful graphs regarding transparency of the results when 
dealing with small sample sizes. Such graphs could clearly 
show where standard deviations come from, particularly if 
subgroup characteristics are reported. Box plots are also a 
very useful way of data presentation since it shows outliers 
and variation.
Nevertheless, as box plot summarizes data, they are more 
meaningful for large sample sizes. The same applies to histo-
grams, they are considered useful in depicting the distribu-
tion of large samples, but they are hard to understand and 
interpret regarding the IIV for the small samples [65, 69]. 
Bar charts are not recommended since they cannot say much 
more than a table and, moreover, they do not help reveal the 
distribution of data at all, since the same bar chart could be 
created based on different distributed data sets [69].
Another way of favorable data reporting are tables that 
consider criteria beyond the central tendencies and dis-
persion measures, including more parameters that could 
uncover data distribution like min–max, median, interquar-
tile range, coefficient of variation, etc. In this way, readers 
get a clearer picture of data distribution and direction of 
variation. For instance, Brindani et al. reported on central 
tendencies and described the data distribution from their 
sample by additional parameters [70]. This type of approach 
may be useful to better highlight the IIV.
In the end, reporting on outliers could be considered a 
good way to present subjects responding in an atypical way 
and, thus, indicate eventual IIV. The search for homogenous 
data has somehow demonized outliers in research. However, 
when dealing with IIV, outliers can be a precious resource 
to better understand the differential response to the con-
sumption of plant food bioactives and could serve to further 
explore the reasons behind extreme responses. Once con-
firmed that any potential outlier is not the result of an analyt-
ical artifact, it should be considered as robust data indicating 
individual variability. Their exclusion from statistical tests 
may be justified but reporting on them is advisable.
Overcoming challenges in reporting inter‑individual 
variation
The quality of reporting of clinical trials is a critical part 
of their overall quality as it allows readers to judge other 
elements in the quality domain (the design, conduction, 
analysis and clinical implications) and make conclusions 
about the reliability of their reported benefits and harms 
[71]. For more than two decades, an enormous effort was 
put by experts in clinical research into increasing the qual-
ity of reporting, with the introduction of the CONsolidated 
Standards Of Reporting Trials (CONSORT) Statement 
being a pillar. The initial statement was published in 1996 
[72], further updated in 2001 [11], and 2010 [73], and sup-
plemented with 15 official guidelines for different types of 
studies and 14 official extensions that address reporting of 
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different aspects such are study designs, interventions or 
type of data (http://www.equat or-netwo rk.org/). It has been 
confirmed that the introduction of these guidelines and their 
acknowledgment by the scientific community significantly 
improved the reporting quality.
There are still areas in trial reporting that remain insuf-
ficiently described and defined, with contradictory opinions 
or addressed even as “controversies” or (mis)uses in clinical 
research, such as multiplicity of data, co-variate adjustment 
vs. subgroup analysis, assessing individuals benefits and 
risks from clinical trials data, or interpretation of surprising 
results [24]. At the same time, most of these challenging top-
ics are considered highly relevant for assessing the impact 
of IIV, using trial data for identifying those who will benefit 
the most, or with the least harm. For example, it is widely 
accepted that subgroup analyses, especially if performed 
post hoc, may be misleading and could bring a high risk of 
false conclusions that very often cannot be confirmed by 
subsequent studies and may have detrimental consequences 
[13]. However, if conducted and reported properly, analy-
ses of IIV on trial level (e.g., effects in different subgroups) 
could lead to more precise recommendations, provide sup-
porting evidence for making substantiated decisions, and 
could help (re)building the trust of patients/consumers [74]. 
Acknowledging this, the International Committee of Medi-
cal Journal Editors recommends stratifying reporting stat-
ing: “Separate reporting of data by demographic variables, 
such as age and sex, facilitate pooling of data for subgroups 
across studies and should be routine, unless there are com-
pelling reasons not to stratify reporting, which should be 
explained” [75]. A list of additional sets of criteria to test 
the credibility of subgroup analyses includes testing whether 
the effect (1) is consistent across studies, (2) can it be the 
result of a chance, (3) is there a biological reason for the 
observed effect, (4) is the reported evidence from within- or 
between-study comparison, (5) is it defined a priory or it is 
a post hoc [76]. More detailed guidelines on statistical issues 
associated with subgroup analysis have been addressed in 
previous publications [73, 77] with the general conclusion 
that more clear and complete reporting of subgroup analyses 
and similar models of analyzing IIV should be encouraged. 
Last, efforts should also be paid in reducing, as much as 
possible, sources of variability not directly related to physio-
logical conditions but to analytical constraints. In this sense, 
errors in the selection and measurement of some biomarkers 
of intake and effect that may condition the assessment of 
the individual response should be overcome. A deep effort 
and investment should be carried out in the development 
of standardized methodologies for the analysis of specific, 
reliable, and reproducible biomarkers [78, 79]. This would 
further favor the comparison of the reported results.
Authors’ awareness is likely another challenge to be over-
come. Although the interest in the differential individual 
response to the consumption of plant food bioactives is 
growing, as demonstrated by the increasing number of 
publications in the field [15], the number of works dealing 
with this topic is rather scarce if compared to the number of 
publications in the field. Besides more research approaches 
addressing this topic from the study design, further efforts 
are required to report the putative IIV existing in any study. 
By considering the recommendations on reporting indicated 
in the dictionary of this QI (Table 1), authors may endow 
their works with valuable information on the existing IIV. 
Small efforts during the preparation of their manuscripts 
may provide a plethora of valuable information and ben-
efits. The authors would benefit from the increased quality 
of their manuscripts and research, while the whole scientific 
community would benefit from the availability of this key 
information. This work presents the consensus of a signifi-
cant part of the scientific community in the field. Adopting 
this consensus on reporting guidelines will enable the full 
appraisal of the trial conducted and will boost the possi-
bilities to pool research data to gain further evidence. In 
summary, minor changes in the way we report data may 
lead to major developments in the field of plant bioactives at 
the individual level, moving with the times to favor suitable 
strategies for personalized nutrition.
Finally, although the POSITIVe QI was tailored to 
address the need for a better reporting of inter-individual 
variation in response to plant bioactives, it might be con-
sidered for non-plant bioactive compounds and as a starting 
point to address similar issues in other related areas, includ-
ing precision medicine, public health, pharmacokinetics or 
toxicology [80–82]. Further validation of its use on these 
fields by collaborative networks is suggested.
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